Drugs / Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes
Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03665675 | Nov 2020 → Aug 2026 overdue | adenoviridae infectious disease, cytomegalovirus infection, disease related to hematopoietic stem cell transplant, disease related to solid organ transplantation | Sumithira Vasu | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT03425526 | Mar 2018 → Jan 2027 expected | hematopoietic and lymphoid cell neoplasm, immunodeficiency disease | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03425526 ↗ |
| Modality | Cell therapy | “donor T cell therapy” NCT03425526 ↗ |
| Route | Intravenous | “Given IV” NCT03425526 ↗ |